BioSpace News Archive

The company said its Phase II herpes drug did not meet its primary endpoints and will terminate the program.

Allergan announced positive results from its oral Phase IIb/III CGRP antagonist, atogepant. Allergan said atogepant showed a statistically significant reduction in monthly migraine days.

The medical device market was about $521.2 billion last year and is projected to hit $674.5 billion by 2022. Here’s a look at the top 10 medical device companies in the world this year.

Elizabeth Holmes and beleaguered Theranos finally caught a break. Last week U.S. Magistrate Judge Nathanael Cousins shot down the hopes of some investors in filing a class action lawsuit against the company.

Roche is launching its CoaguChek Vantus system, which allows patients to self-test for their anticoagulant therapy.

The U.S. Food and Drug Administration (FDA) approved AbbVie and Roche’s combination of Venclexta in combination with Rituxan (rituximab) to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion in patients who have received at least one previous therapy.

Translate Bio, headquartered in Lexington, Massachusetts, and Paris-based Sanofi are teaming up to develop five vaccines.

Billionaire biotech entrepreneur Patrick Soon-Shiong has his eyes set on taking his newly formed oncology-focused Nant public this year.

The company said it will use the funds to advance its pipeline of novel antibiotics to treat serious bacterial infections, as well as expand its sales staff.

Alexion Pharmaceuticals is forging a partnership with Complement Pharma to co-develop a C6 complement inhibitor.